Comparison of the effects of sitagliptin and mitiglinide/voglibose fixed-dose combination tablets on glucose metabolism in patients with uncontrolled type-2 diabetes mellitus.

Not Applicable

• Conditions: type-2 diabetes mellitus

• Registration Number: JPRN-UMIN000008274
• Lead Sponsor: niversity of Occupational and Environmental Health, Japan

Brief Summary

Increasing the dose of STG to 100 mg/day reduces blood glucose levels from midnight to early morning in patients with postprandial hyperglycemia who have HbA1c values of approximately 7%, FPG levels of approximately 120 mg/dL, and postprandial glucose levels >200 mg/dL. In addition, switching to MIT/VOG improves fluctuations in blood glucose levels and postprandial hyperglycemia.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-27
• Study Completion: 2014-01-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients treated with a sulfonylurea (SU), alfa-glycosidase inhibitor (alfa-GI) or insulin secretagogue (glinide). 2) Patients with diabetic ketoacidosis, diabetic coma/precoma or type-1 diabetes mellitus. 3) Patients with severe infection or serious trauma, or those operated recently or scheduled for surgery. 4) Patients with moderate or severer renal disorder (creatinine level 1.5 mg/dL (men) or 1.3 mg/dL (women)). 5) Patients with liver disorder (AST or ALT level 3 times the normal upper limit). 6) Women who are pregnant or suspected of being pregnant. 7) Women who are breastfeeding. 8) Patients with a history of hypersensitivity to an ingredient of the study drugs. 9) Other patients judged to be ineligible by the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified